29
Participants
Start Date
January 15, 2016
Primary Completion Date
March 19, 2019
Study Completion Date
March 19, 2019
ATRA
Administered orally on D1-15 of each 28 day cycle.
Gemcitabine
Intravenous Infusion on D1,8 and 15 of each 28 day cycle.
Nab-paclitaxel
Intravenous Infusion on D1,8 and 15 of each 28 day cycle.
Cambridge University Hospitals NHS Foundation Trust, Cambridge
Barts and The London NHS, St Bartholomew's Hospital, London
Guy's and St Thomas' NHS Foundation Trust, London
Imperial College NHS Trust, London
Collaborators (2)
Medical Research Council
OTHER_GOV
Celgene Corporation
INDUSTRY
Cancer Research UK Cambridge Institute
OTHER
King's College London
OTHER
Royal Free Hospital NHS Foundation Trust
OTHER
Imperial College Healthcare NHS Trust
OTHER
Institute of Cancer Research, United Kingdom
OTHER
Cambridge University Hospitals NHS Foundation Trust
OTHER
Barts & The London NHS Trust
OTHER